We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Predicts Coronary Disease Death Risk

By LabMedica International staff writers
Posted on 05 Jul 2018
Print article
Image: The Access AccuTnI+3 Reagent is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of cardiac troponin I (cTnI) levels in human serum and plasma using the Access 2 Immunoassay System to aid in the diagnosis of myocardial infarction (Photo courtesy of Beckman-Coulter).
Image: The Access AccuTnI+3 Reagent is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of cardiac troponin I (cTnI) levels in human serum and plasma using the Access 2 Immunoassay System to aid in the diagnosis of myocardial infarction (Photo courtesy of Beckman-Coulter).
Cardiovascular (CV) disease is a major cause of morbidity and mortality, and is associated with activation of the renin-angiotensin system (RAS). Angiotensin converting enzyme 2 (ACE2) is an endogenous regulator of the renin angiotensin system.

Increased circulating ACE2 predicts adverse outcomes in patients with heart failure (HF), but it is unknown if elevated plasma ACE2 activity predicts major adverse cardiovascular events (MACE) in patients with obstructive coronary artery disease (CAD).

Scientists at the University of Melbourne (Parkville, Australia) and their international colleagues prospectively recruited 79 consecutive patients aged >18 years between November 2004 and January 2006 after referral to a tertiary cardiovascular center for a coronary angiogram to investigate suspected CAD. Fasting blood samples were collected at the time of admission for measurement of kidney function, lipids, and troponin. The Access AccuTnI assay was used to measure plasma troponin.

For plasma ACE2 measurement, blood was collected within 48 hours of presentation into lithium heparin tubes, and plasma was obtained by centrifuging blood at 3,000 rpm at 4 °C for 10 minutes and stored at –80 °C until tested. Plasma ACE2 activity was measured within two years after all samples were collected. The catalytic activity of ACE2 was measured using a validated, sensitive quenched fluorescent substrate-based assay. The rate of substrate cleavage was determined by comparison to a standard curve of the free fluorophore.

The scientists reported that the median (IQR) plasma ACE2 activity was 29.3 pmol/mL/min (range: 21.2–41.2). Over a median follow up of 10.5 years, MACE occurred in 46% of patients (36 events). Above median levels of ACE2 (>29.3 pmol/mL/min) were significantly associated with a higher incidence of MACE and HF hospitalization compared with those with below-median ACE2. Over the follow-up period, there were 18 deaths, 19 myocardial infarcts and 16 hospitalizations with HF. The primary endpoint of MACE, a composite of CV mortality, HF hospitalization or MI occurred in 36 patients.

The authors concluded that their study demonstrated that elevated plasma ACE2 activity is an independent predictor of MACE in patients with obstructive CAD. Louise M. Burrell, MBChB, MRCP, MD, FRACP, a professor of Cardiology and senior author of the study, said, “We have come a long way in treating coronary artery disease but certain patients continue to be at high risk of dying. This new blood test helped identify such patients who may derive benefit from more aggressive treatment.” The study was published on June 13, 2018, in the journal Public Library of Science ONE.

Related Links:
University of Melbourne

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Coagulation Analyzer
CS-2400

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.